The medical device industry is an industry dealing with multiple types of products covering a wide range of applications. As the safety and effectiveness of medical devices are vital to human health, the products must be managed by strict regulations according to the different risk levels. A total product life cycle regulatory system including product design, manufacture, premarket gate keeping, and postmarket monitoring is a common framework for medical device regulations. However, the variety and innovativeness of medical devices are challenging the current regulatory frameworks. Hence, the competent authorities responsible for medical devices worldwide keep renewing their regulatory systems to ensure the safety and effectiveness of medical devices. This review aims to provide an informative review of the regulatory frameworks of medical devices in the United States, Europe, Canada, and Taiwan, with a particular focus on updated regulatory changes in these countries and the current status of global harmonization on medical devices.
Introduction
Statistics provided by BMI Espicom showed that the global medical device market scale was US$323.9 billion in 2015, 1 and it is predicted to grow to US$431.5 billion in 2020 at a compound annual growth rate (CAGR) of 5.7%. This market growth is driven by the global issue of aging and the increased prevalence of chronic diseases.
As the safety and effectiveness of medical devices are vital to human health, the products must be managed by strict regulations according to the different risk levels. In addition, certification procedures for different specifications must be carried out. However, the variety and innovativeness of medical devices are challenging the current regulatory frameworks. Hence, medical device regulations are constantly improved to benefit public health and ensure the application of high-quality and effective technologies.
Medical device regulatory reform has been promoted by global harmonization and streamlining. Subsequently, relevant international organizations have been established, including the International Medical Device Regulators Forum (IMDRF) and the Asian Harmonization Working Party (AHWP). IMDRF, founded in 2011, has provided a forum for discussion of how to harmonize global medical device regulations. The current regulatory members of IMDRF are Australia, Brazil, Canada, with the Act, medical devices are classified into 3 classes, class I, II, and III, depending on their risk levels. The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) is responsible for regulating medical devices in the US market. FDA medical device regulations including the quality system, clinical investigation, premarket approval, and postmarket management are discussed in this article. Table 1 compares the regulations of the US, Europe, Canada, and Taiwan.
Quality System
The US Quality System Regulation (QSR) for medical devices is based on Title 21, part 820 of CFR (21 CFR 820). The US FDA requires manufacturers to implement Good Manufacturing Practice (GMP) to ensure that medical devices meet the requirements of QSR, except for a few Class I devices that are not supplied sterile. However, manufacturers of devices exempted from the GMP by the US FDA are still requested to maintain complaint files (21 CFR 820.198) and general requirements regarding records (21 CFR 820.180).
Clinical Investigation
Medical device clinical studies in the US are divided into significant risk (SR) and nonsignificant risk (NSR) device studies. To conduct an SR device study, an investigational device exemption (IDE) application is required. The sponsors must have approval from both the FDA and an institutional review board (IRB) prior to beginning the study. Although NSR device studies require only IRB approval, the sponsors must comply with the abbreviated IDE requirements, such as labeling, informed consent, monitoring, and record keeping during the study.
Premarket Approval
Premarket Notification, also known as 510(k), and Premarket Approval are the major premarket submissions for manufacturers planning to market their products in the US. The key point of review of 510(k) is to determine whether the new device is substantially equivalent (SE) to a legally marketed device, while the key point of PMA review is to demonstrate the safety and effectiveness of the device through, for example, technical documents, preclinical laboratory studies, and clinical data.
Postmarket Management
The postmarket requirements on medical devices in the US include tracking systems, reporting of device malfunctions, serious injuries or deaths, and establishment registration. Additionally, the US FDA requires postmarket surveillance studies (FDCA section 522) for some class II or class III devices that are life-sustaining or life-supporting, implanted in the body for more than 1 year, significantly used in pediatric populations, or whose failure would likely cause serious adverse health consequences.
Regulatory Updates
Recognizing that cybersecurity is important throughout the product life cycle, the US FDA issued the draft guidance "Post-market Management of Cybersecurity in Medical Devices" on January 22, 2016, to advise the manufacturers to monitor cyber threats continually. PMA application is required for surgical mesh for the transvaginal repair of a prolapsed pelvic organ, since such medical devices were reclassified from Class II to Class III on January 4, 2016. Recently, the challenge to the regulatory frameworks posed by the prosperous development of the medical device industry has triggered the reform of medical device management systems in the EU. In 2012, the European Commission proposed two regulation proposals to integrate the current directives into Medical Devices Regulations (MDR) and In Vitro Diagnostic Devices Regulations (IVDR). 3, 4 Both proposed regulations expand the scope, better the notified bodies, strengthen market surveillance, and improve the traceability of products.
The following provides a summary of the current framework of medical device management and the changes that will confront manufacturers when the new regulations enter into force.
Quality System
EN ISO 13485: 2012 is a harmonized standard applied by manufacturers to implement the quality system in the EU. For 
Premarket Approval
CE marking is a legal requirement for all medical devices to be sold in the EU. CE marking affixed on the product represents its compliance with relevant Directives. To obtain CE certification, manufacturers must decide an appropriate conformity assessment route based on the classification of their devices. For class I medical devices without a measuring function or those not supplied sterile, only the declaration of conformity is required prior to affixing the CE marking. All other devices need to be verified and certified by notified bodies.
Postmarket Management
The competent authorities of each member state in Europe are responsible for the postmarket surveillance, including adverse event reporting, vigilance reporting, and postmarket clinical follow-up. In order to enhance the transparency of market surveillance, the European Databank on Medical Devices (EUDAMED) was established for exchanging legal information. In addition to vigilance information, EUDAMED contains data such as manufacturer registration, certificates issued, and clinical investigations.
Regulatory Updates
The MDR and IVDR are scheduled to be published in 2017. The changes from current directives to the two proposed regulations are as follows:
The notified body must randomly conduct unannounced on-site audits of manufacturers, suppliers, or subcontractors at least once every 5 years.
To improve the traceability of medical devices, a Unique Device Identification (UDI) system will be implemented, and the data will also be included in EUDAMED to improve the databank. Devices without medical purposes such as noncorrective contact lenses, equipment for liposuction, and laser equipment for hair removal are included in the scope of MDR.
Whether the reprocessing of single-use devices (SUDs) is permitted or not depends on the decision of each member state. A company allowed to reprocess SUDs must assume the manufacturers' obligations stipulated in the MDR and ensure that the safety and effectiveness of the proposed device is equivalent to those of the original device. In Vitro Diagnostic Devices will be regulated by a new classification scheme. Classes A, B, C, and D, based on risk levels, will be addressed. IVDs with higher risk classification require a notified body to conduct a conformity assessment. 
Quality System
Health Canada requires manufacturers of class II, III, and IV medical devices to establish a quality system based on the corresponding national standard CAN/CSA ISO 13485:2003. According to CMDR, class II medical device manufacturers are allowed to exclude design controls from their quality management system, while class III and IV medical device manufacturers must meet the full quality system requirements. As elements of medical device license applications, only quality system certificates issued by Canadian Medical Devices Conformity Assessment System (CMDCAS)-recognized registrars will be accepted upon submission.
Clinical Investigation
To conduct a clinical study of class II, III, or IV devices in Canada, an application for Investigational Testing Authorization (ITA) is required. Although class I medical devices are excluded from the ITA, the sponsors and investigators must assume responsibilities and obligations similar to those applied to the clinical trials of medical devices of other classes. The submission documents required for the ITA are detailed in the guide "Preparation of an Application for Investigational Testing-Medical Devices." It is notable that sponsors must obtain the approval letter from an institutional Research Ethics Board prior to ITA submission for class III or IV devices.
Premarket Approval
To sell class I medical devices in Canada, manufacturers must obtain medical device establishment licenses (MDEL). The MDEL holder must submit an annual review application to maintain its validity by April 1 of each year. In spite of exemption from the medical device licensing requirements, class I devices are still regulated to satisfy the safety and effectiveness requirements (sections 10-20) and labeling requirements (section 21) of the CMDR. For class II, III, and IV devices, manufacturers must apply for medical device licenses for marketing in Canada. Annual license renewals are required by November 1.
Postmarket Management
Health Canada requires medical device manufacturers, importers, and distributors to meet the postmarket requirements under CMDR, including maintenance of distribution records (section 52-56), complaint handling (section 57-58), mandatory problem reporting (section 59-62), and recall (section 63-65).
Regulatory Updates
Noncorrective contact lenses (NCCL), also known as decorative contact lenses, have been regulated in Canada as class II medical devices since July 29, 2015. Manufacturers of the products must apply for a medical device license. The mandatory implementation began on July 16, 2016. 
Quality System
The TFDA requires manufacturers to establish a quality system based on part 3 of the Good Manufacturing Practices for Medical Devices of the Pharmaceutical Good Manufacturing Practice Regulations, which is harmonized with ISO 13485:2003. It was set forth that all medical devices intended to launch in Taiwan and those used in clinical trials conducted in Taiwan must comply with the GMP requirements. For domestic manufacturers, the TFDA authorized 4 organizations to conduct GMP on-site inspections of medical devices. To obtain the quality system certificate, foreign manufacturers can follow one of 4 modes: full quality system documentation (QSD) review, simplified mode for US manufacturers, simplified mode for EU manufacturers, and overseas manufacturer inspection. When the application is approved, the manufacturer will receive a GMP/QSD approval letter valid for 3 years.
Clinical Investigation
For conducting a clinical trial as defined in article 8 of the Medical Care Act, the sponsors must have both IRB and TFDA approvals prior to beginning the study. Clinical trial applications to TFDA or IRB may be submitted simultaneously. It is notable that applications for US FDA-approved clinical trials can be simplified by fast track review.
Premarket Approval
In accordance with article 40 of the Pharmaceutical Affairs Act, medical device companies intending to market their products in Taiwan must apply for medical device licenses for devices in all classes. The registration requirements are based on "Regulations for Registration of Medical Devices," and the dedicated application documents differ among the 3 classes ( 
Postmarket Management
The postmarket management system on medical devices in Taiwan includes market sampling, follow-up audit, reporting of adverse reactions, and recall. Moreover, the TFDA requires manufacturers of high-risk medical devices, for example, drugeluting stents, cardiac ablation systems, and intraocular lenses, to conduct a safety monitoring plan and submit obligatory periodic safety update reports within the specified time period.
Regulatory Updates
Good Clinical Practice for medical devices based on ISO 14155:2011 was announced in October 2015, and implemented on January 1, 2016. 8 Since July 1, 2016, the TFDA allows manufacturers of infrared ear thermometers, clinical electronic thermometers, surgical drapes, and surgical gowns to use conformity declaration of preclinical testing to replace testing report review for registration applications. This conformity declaration is only available for manufacturers that own similar approved devices in Taiwan with the same classification number. 9 Products with corrective lenses, such as swimming goggles, skiing goggles, racquetball goggles, and diving goggles, were officially categorized as class I medical devices on September 1, 2016.
10

Conclusion and Discussion
The medical device industry, which integrates technologies across biomedical, materials, mechanics, and electronics domains, plays a crucial role in the biotechnology industry.
Because of the global issue of aging populations, the increased prevalence of chronic diseases, and high demand for health care, the medical device market is growing rapidly. As the safety and effectiveness of medical devices are vital to human health, the products must be governed by strict regulations based on the different risk levels. However, the challenges posed to the current regulatory frameworks by the variety and innovativeness of medical devices are driving the reform of regulatory systems worldwide. Recently, more and more medical devices incorporating wireless, Internet, or regional network technology are applied widely in hospitals, leading to an estimated market value of US $285 billion for Internet-connected health care products by 2020.
11 However, the safety of these products, like that of other computer systems, is threatened by the unprecedented challenges from cyberattacks. Regarding the impacts of cybersecurity threats on the devices, the US FDA expended great efforts to develop relevant guidelines to strengthen and maintain the security of these devices. These guidelines suggest that manufacturers manage cybersecurity vulnerability throughout the life cycle of the medical devices. Furthermore, it is important that manufacturers keep improving security systems while processing maintenance of the devices. In the EU, in addition to the security requirements in EN 62304:2015 (clause 5.2.2), manufacturers are required to implement risk management of cybersecurity vulnerabilities based on EN ISO 14971:2012 to protect the devices and personal data from cyberattacks. 12 Although there is no dedicated guidance for medical devices in the EU, cybersecurity for devices is still regulated under different statutes, including a proposed NIS directive and guidelines for IoT devices. In both the US and Europe, the relevant guidelines or rules regarding cybersecurity are under constant development and discussion because cybersecurity is currently a complex issue for the health care sector.
As medical device technology has greatly improved, and aesthetic medicine has now become a booming industry, medical devices are no longer limited to clinical purposes; they are further applied in cosmetic surgery. However, the risks caused by these products are usually neglected. Therefore, higher-level regulatory management of such devices is applied worldwide. In the EU, devices without medical purposes such as noncorrective contact lenses are intended to be included in the scope of new MDR. Whether for decorative or corrective purposes, all contact lenses pose the same risks because of direct contact with the cornea, such that ulcers, keratitis, conjunctivitis, iritis, or even blindness can occur if decorative contact lenses are worn improperly. Also, the US FDA requires manufacturers to obtain a 510(k) Clearance Letter before marketing decorative contact lenses in the US. Additionally, it is illegal to sell these products without a prescription. In July 2015, Health Canada categorized decorative contact lenses as class II medical devices that are governed under CMDR, with license applications required. In Taiwan required to apply for medical device licenses for devices in all classes. In brief, medical device regulations must be continuously revised to ensure the safety of consumers even if the products are not intended for medical purposes. The innovative technology in medical devices drives the regulatory reform and also contributes to global health. However, regulations vary from nation to nation, presenting barriers for patients who need innovative, safe, and effective treatments. To facilitate the development of the medical device industry and ensure the provision of advanced medical devices that benefit patients without hurdles, global regulations must be harmonized. Global harmonization aims to reduce regulatory differences worldwide, eliminate immoderate or countryspecific requirements, and build up a consistent and transparent international regulatory management system. Currently, IMDRF has studied and discussed several topical issues on medical device harmonization, including UDI implementation, the MDSAP pilot, medical devices with software, Good Regulatory Review Practices, and Regulated Product Submission (RPS). The implementation of the MDSAP pilot can prevent multiple audits of medical device manufacturers and speed up the launch of their products. By August 2016, approximately 85 audits had been performed under MDSAP. 13 Furthermore, in order to unify the format of message exchanges among each member, the RPS work group of IMDRF has designed a comprehensive Table of Contents (ToC) for premarket applications. The regional pilot, initiated on October 1, 2015, was undertaken by Canada, the US, the EU, Brazil, Australia, and China. As of August 2016, premarket applications of 29 devices had been submitted based on the ToC.
14 Another ongoing program is the National Competent Authority Report (NCAR) exchange program. This program aims to rapidly adopt field safety corrective actions in all concerned geographies to avoid serious impacts on health. According to statistics provided by the NCAR work group of IMDRF, 8 of 26 NCARs from October 2015 to September 2016 did not fulfill the requirements of IMDRF/NCAR WG/N14, and 56% of the valid reports were circulated by non-EU countries. 15 These findings suggest that it is essential to develop new confidentiality arrangements among Management Committee Regulators to promote NCAR exchanges and wider participation in the program.
Despite the efforts of IMDRF, significant challenges remain. Diversity in regulatory systems, cultures, economies, technical expertise, government policies, and extra regulatory burdens for manufacturers could be obstacles to harmonization. For example, the primary challenge encountered in the MDSAP pilot, implemented almost 3 years ago, is the low participation of manufacturers. According to the MDSAP Mid-Pilot Status Report published by the FDA, approximately 330 medical device manufacturing sites should be interested in joining this program by the end of 2016. 16 However, only about 85 audits had been conducted by August 2016. In this report, the FDA noted that "manufacturer participation is vital for the success of the program." Several issues lead to low participation in the MDSAP pilot. One of them is the limited number of Auditing Organizations (AOs). Under the MDSAP pilot, only 13 AOs are authorized to conduct regulatory audits, and the number of AOs is even lower in some member countries. Moreover, upcoming regulatory changes in the EU and increased regulatory burdens for small and medium enterprises participating in the program make the program unattractive, so manufacturers are hesitant to participate. IMDRF believes that improving the program attractiveness and increasing the number of AOs to conduct MDSAP audits would increase participation in the future.
According to the IMDRF Strategic Plan 2020, the following tasks from 2016 to 2020 aim to support innovation in medical devices and benefit patients by ensuring safe and effective devices are applied in a timely manner. 17 IMDRF will focus on strengthening postmarket surveillance and building up efficient premarket review. IMDRF has also set constant communication and collaboration with other regulatory authorities as their mission. Harmonization is a continuous process and longterm undertaking. In order to overcome the challenges discussed above and many others, comprehensive strategies and plans must be developed before the policy is put into practice. Although in the beginning, industries may face new compliance burdens, in the long run, firms will be able to reduce the time and cost for marketing approval in various countries. Moreover, smoother governmental regulatory exercises, more frequent international trade, and better public health protection can be expected.
